Semaglutide tied to survival in non-Hodgkin lymphoma on anthracyclines
In two matched groups of 994 adults, semaglutide was linked to hazard ratios of 0.20 for death and 0.47 for major heart events against unexposed patients.
994 participants
Limit: Semaglutide users had median follow-up of 584 days, limiting assessment of longer-term survival
Edited by Boris Djordjevic · AgingResearch.News
In an observational database study, researchers compared two matched groups of 994 adults with non-Hodgkin lymphoma, a cancer of the lymphatic system, who received anthracycline chemotherapy. One group used semaglutide during chemotherapy; the other did not. Median follow-up was 584 days and 730 days, respectively.
Semaglutide use was associated with a hazard ratio of 0.20 for death compared with no exposure. Hazard ratios compare how often events occur over time. It was also linked to lower risks of major cardiovascular events (hazard ratio 0.47), heart attacks (0.41), heart failure (0.60), and atrial fibrillation or flutter, an irregular heartbeat (0.42). Acute kidney injury, sudden kidney damage, had a hazard ratio of 0.29. For hospitalizations, the range of likely values included no difference. Stroke risk did not differ significantly.
Why it matters
Heart damage from anthracycline chemotherapy is a major cause of illness and death in non-Hodgkin lymphoma survivors.
Caveats
Because this was an observational database study rather than a randomized trial, unmeasured differences between patients may have influenced the results. The findings were presented as a conference abstract and apply specifically to adults with non-Hodgkin lymphoma treated with anthracyclines, not other cancers or chemotherapy regimens.
The paper
National & Kapodistrian University of Athens Medical School
ESC Congress 2026 Abstract, Oct 26, 2026
Presented at ESC Congress 2026
